Alkem Labs to acquire Dronabinol assets for Rs 71 crore from AbbVie

The assets related to Dronabinol include domain names and trademarks pertaining to 'Marinol', New Drug Application (NDA) registration with US Food and Drug Administration (USFDA) for Marinol, logos, patents designs, know-how, technical and manufacturing instructions, inventory, manufacturing equipment, and such items, Alkem Laboratories said in a filing to BSE.

New Delhi: Drug firm Alkem Laboratories on Tuesday said it has entered an asset purchase agreement with AbbVie Inc, USA, for acquisition of certain assets related to active pharmaceutical ingredient, Dronabinol, for over USD 10 million approximately Rs 71 crore).

The assets related to Dronabinol include domain names and trademarks pertaining to 'Marinol', New Drug Application (NDA) registration with US Food and Drug Administration (USFDA) for Marinol, logos, patents designs, know-how, technical and manufacturing instructions, inventory, manufacturing equipment, and such items, Alkem Laboratories said in a filing to BSE.

Read Also: Alkem Labs gets EIR from USFDA for St.Louis facility

The cost of acquisition is cash consideration of USD 10 million-plus suitable working capital adjustments on closing, it added.

The objects of the acquisition are, "The company shall own the NDA and associated assets and will use these to commercially exploit both branded and generic sales in the US," Alkem Laboratories said.

Read Also: Alkem Labs Bioeguivalcnce Center at Taloja clears USFDA inspection